HanchorBio to Hold May 11 Investor Presentation Ahead of Planned Taiwan Innovation Board Listing
Clinical-stage biotech to outline platform, lead pipeline assets, and partnering progress ahead of planned market debut
[Taipei, Shanghai, San Francisco | May 8, 2026] – HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, today announced that it will hold an investor presentation on May 11 ahead of its planned listing on the Taiwan Innovation Board later this month.
The presentation is expected to highlight HanchorBio’s proprietary FBDB™ platform, progress across its lead clinical programs, business development activity, and broader growth strategy as the company prepares for its next phase as a publicly listed biotech.
Founded in 2020 by Scott Liu, Ph.D., Founder, Chairman, and Chief Executive Officer, HanchorBio is focused on developing multifunctional biologics designed to address complex disease biology across innate and adaptive immune pathways. The company currently has eight drug candidates across research, development, and process development, with HCB101 and HCB301 as its two most advanced clinical-stage programs.
HCB101, an AI-guided, structurally engineered SIRPα-IgG4 Fc fusion protein targeting the CD47-SIRPα axis, is being evaluated in an ongoing Phase 1b/2a study and has demonstrated antitumor activity across multiple solid tumor settings, including head and neck, gastric, triple-negative breast, and colorectal cancers. The program has received the U.S. Food and Drug Administration Orphan Drug Designation for gastric cancer.
HCB301 is a tri-functional fusion protein designed to address three key immune escape pathways in tumors. Phase 1 clinical trials have been initiated in the United States, mainland China, and Taiwan.
“Our strategy is centered on building differentiated best-in-class and first-in-class drug programs with global development and partnering potential,” said Scott Liu, Ph.D., Founder, Chairman, and Chief Executive Officer of HanchorBio. “We believe HCB101 and HCB301 represent two distinct examples of how our platform can generate novel biologics designed to address important limitations in current immuno-oncology approaches.”
HanchorBio has also established an early business development track record. In 2024, the company entered into a licensing agreement for HCB101 with a total potential value of up to US$202 million, granting Henlius exclusive development and commercialization rights in mainland China and certain other territories. The company is also engaged in global partnering discussions with multiple international pharmaceutical companies, including certain partners conducting due diligence.
Beyond oncology, HanchorBio is advancing additional biologic candidates based on the FBDB™ platform, including HCB206 for autoimmune diseases, which is expected to progress toward clinical development. In April 2026, the company also announced a collaboration with National Yang Ming Chiao Tung University to expand its capabilities in AI-enabled drug discovery.
HanchorBio has attracted backing from institutional investors, including Anfu Healthcare and Panacea Venture. Dr. Liu currently holds approximately 40% of the company’s shares, reflecting significant founder ownership and long-term alignment with shareholders.
The planned Taiwan Innovation Board listing would mark an important milestone in HanchorBio’s transition from a privately funded R&D-stage biotech to a broader capital-markets-facing clinical-stage company. The company intends to continue advancing HCB101 and HCB301, pursue additional strategic collaborations, and prepare future IND submissions in autoimmune disease as it expands its pipeline and global development footprint.
About HanchorBio
Based in Taipei, Shanghai, and the San Francisco Bay Area, HanchorBio (7827.TPEx) is a global clinical-stage biotechnology company focused on immuno-oncology and immune-mediated diseases. The company’s proprietary Fc-based designer biologics (FBDB™) platform enables the design of multi-functional biologics intended to modulate innate and adaptive immune pathways with structural control over safety, exposure, and manufacturability. HanchorBio is advancing a portfolio of differentiated biologics designed to address significant unmet medical needs through innovative molecular engineering and scalable CMC strategies.